1.

A multi-center, prospective, open-label, clinical trial to assess the safety and the efficacy of a new intravenous immune globulin ( IP ) in patients with idiopathic (immune) thrombocytopenic purpura.

2.

A Multicentric open label phase III study to evaluate the safety and efficacy of Rituximab (Zenetech) in patients with relapsed or refractory low grade or follicular non hodgkin’s lymphoma. (Study code: Zen-01/2006)